TG4070
Category: 2025
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
MPOX
Transgene’s Combined General Meeting of May 22, 2026
AG 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
AG 2026
Transgene Provides Business and Financial Update for Q1 2026
Q1 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
TG4050
Transgene to Participate in Upcoming Investor Meetings
Investor meetings
2025 Full-year results and business update
link to webcast
Transgene Announces Financial Calendar for 2026
financial calendar 2026
Transgene to Participate in Upcoming Investor Meetings
investors 2026